H.C. Wainwright has adjusted its price target for Annovis Bio (ANVS, Financial), reducing it from $30 to $12 while maintaining a Buy rating for the stock. This revision is attributed to the effects of the company's latest equity financing in February, along with the anticipated future issuance of more equity and the exercise of warrants. These financial factors have influenced the firm’s decision to lower its target price.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 5 analysts, the average target price for Annovis Bio Inc (ANVS, Financial) is $29.40 with a high estimate of $72.00 and a low estimate of $8.00. The average target implies an upside of 815.89% from the current price of $3.21. More detailed estimate data can be found on the Annovis Bio Inc (ANVS) Forecast page.
Based on the consensus recommendation from 6 brokerage firms, Annovis Bio Inc's (ANVS, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
